Lantern Pharma公司宣布，其针对旗下药物Lp-300在非吸烟非小细胞肺癌（NSCLC）患者中进行的Harmonic™二期临床试验，向美国食品药品监督管理局（FDA）提交的C类会议请求已获得成功结果。这一积极进展标志着该试验方案与监管路径获得了关键性的初步认可，为后续临床开发奠定了重要基础。
Lantern Pharma公司宣布，其针对旗下药物Lp-300在非吸烟非小细胞肺癌（NSCLC）患者中进行的Harmonic™二期临床试验，向美国食品药品监督管理局（FDA）提交的C类会议请求已获得成功结果。这一积极进展标志着该试验方案与监管路径获得了关键性的初步认可，为后续临床开发奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.